Hypoxia-induced overexpression of stanniocalcin-1 is associated with the metastasis of early stage clear cell renal cell carcinoma by Xin Ma et al.
Ma et al. Journal of Translational Medicine  (2015) 13:56 
DOI 10.1186/s12967-015-0421-4RESEARCH Open AccessHypoxia-induced overexpression of stanniocalcin-1
is associated with the metastasis of early stage
clear cell renal cell carcinoma
Xin Ma†, Liangyou Gu†, Hongzhao Li, Yu Gao, Xintao Li, Donglai Shen, Huijie Gong, Shichao Li, Shaoxi Niu,
Yu Zhang, Yang Fan, Qingbo Huang, Xiangjun Lyu and Xu Zhang*Abstract
Background: Although metastasis of clear cell renal cell carcinoma (ccRCC) is predominantly observed in late stage
tumors, early stage metastasis of ccRCC can also be found with indefinite molecular mechanism, leading to inappropriate
clinical decisions and poor prognosis. Stanniocalcin-1 (STC1) is a glycoprotein hormone involved in calcium/phosphate
homeostasis, which regulates various cellular processes in normal development and tumorigenesis. This study aimed to
investigate the role and mechanism of regulation of STC1 in the metastasis of early stage ccRCC.
Methods: STC1 mRNA and protein expression was determined in ccRCC surgical specimens, RCC cell lines, and
human kidney tubule epithelial cell line HKC by real-time polymerase chain reaction (RT-PCR) and western blotting.
Immunohistochemistry staining (IHC) and immunofluorescence were also used to examine the expression and
localization of STC1 in ccRCC tissues and cancer cells. Knockdown and overexpression studies were conducted
in vitro in RCC cell lines using small interfering RNAs (siRNA) and lentiviral-mediated gene delivery to evaluate the
role of STC1 in cell proliferation, anchorage-dependent and independent growth, cell cycle control, and migration
and invasion.
Results: STC1 mRNA and protein expression were significantly up-regulated in tumors when compared with
non-tumor tissues, with the greatest increase in expression observed in metastatic tissues. Clinicopathological
analysis revealed that STC1 mRNA expression was associated with Fuhrman tumor grade (P = 0.008) and overall
Tumor Node Metastasis (TNM) staging (P = 0.018). STC1 expression was elevated in T1 stage metastatic tumors
when compared with localized tumors, and was positively correlated with average tumor diameter. Silencing of
STC1 expression by Caki-1 and A498 resulted in the inhibition of cell proliferation, migration, and invasion,
meanwhile down-regulation of STC1 impaired epithelial–mesenchymal transition (EMT) of ccRCC cell lines.
Overexpression of STC1 in Caki-2 enhanced cell growth and proliferation but not migration and invasion. Further
investigation identified hypoxia and HIF-1α as candidate regulators of STC1 expression.
Conclusions: Our findings demonstrate a role for STC1 in metastasis of early stage ccRCC and suggest that STC1
may be a biomarker of potential value both for the prognosis of this disease and for guiding clinical decisions
regarding surgical strategies and adjuvant treatment.
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Renal cell carcinoma (RCC), accounts for 2-3% of all adult
malignancies, and is the second leading cause of death as-
sociated with urological malignant neoplasms. The most
common histological subtype is clear cell RCC (ccRCC),
accounting for approximately 80-90% of all RCCs [1]. The
increasing number of patients presenting with lower stage
disease in recent years is hypothesized to be the result of
the more widespread use of multi-parametric imaging,
which has resulted in an increase in the incidental discov-
ery of renal tumors [2]. For early stage kidney tumors, par-
tial nephrectomy is generally accepted as the standard
approach for removing localized RCC and is associated
with a good prognosis [3,4]. However, the prognosis of pa-
tients with metastatic renal cell carcinoma (mRCC) is ex-
tremely poor. A better understanding of the molecular
mechanism underlying the pathogenesis of RCC is there-
fore needed to provide new biomarkers and therapeutic
strategies for the treatment of this disease.
Stanniocalcin (STC) is a glycoprotein hormone involved
in calcium and phosphate homeostasis, which was originally
discovered as a secretory hormone of the corpuscles of Stan-
nius, an endocrine gland of bony fish [5]. A human ortholog
of fish STC, STC1, has been identified by molecular biology
techniques. Mammalian STC1 is broadly expressed in vari-
ous tissues including heart, lung, liver, adrenal gland, kidney,
ovary, prostate, colon, bone and spleen [6-11]. STC1 appears
to have multiple functions in physiological and pathological
processes, including pregnancy [12], lactation [12], angio-
genesis [13,14], organogenesis [15,16], cerebral ischemia
[17], oxidative stress [18], and apoptosis [19,20]. Whereas
the majority of studies have focused on the calcium-
regulating functions of STC1, accumulating evidence
suggests that STC1 may also play an important role in car-
cinogenesis. Increased STC1 expression has been observed
in many types of cancer, including colorectal cancer, hepato-
cellular carcinoma [21,22], non-small cell lung cancer [23],
ovarian cancer [10], breast carcinoma [24-27] and leukemia
[28]. STC2 was identified from expressed sequence tag
(EST) database searches for sequences related to STC1 [5].
STC2 is expressed in various tissues and associated with sev-
eral types of cancer, and has been identified as a predictor
for aggressiveness and overall patient survival in RCC [29].
Despite recent advances in our understanding of
STC1, the expression pattern, clinical relevance, and bio-
logical role of this protein in ccRCC remains poorly
understood. Recent studies indicate that STC1 expres-
sion is involved in the formation of tumor vasculature
through up-regulation of vascular endothelial growth
factor (VEGF) [13,14], STC1 can induce adaptive re-
sponses to hypoxia in human cancer cells through the
regulation of hypoxia inducible factor-1-alpha (HIF-1α),
a process that is closely associated with carcinogenesis
and the progression of RCC [30,31].In the present study, we examined STC1 mRNA and pro-
tein expression in ccRCC tissues and cell lines. We exam-
ined the correlations between STC1 expression and
clinicopathological features, and evaluated the role of this
protein in the metastasis of patients with early stage ccRCC.
Moreover, we assessed the effects of knockdown and over-
expression of STC1 in vitro on the proliferation, cell cycle
progression, migration and invasion of RCC cells. Finally,




Written informed consent was obtained from all patients
prior to sample collection and the study was approved by
the Protection of Human Subjects Committee of Chinese
People’s Liberation Army General Hospital.
Patients and tissue samples
Tissue specimens were obtained from patients with
ccRCC who underwent partial or radical nephrectomy
at the Chinese People’s Liberation Army (PLA) General
Hospital (Beijing, China). A total of 122 patients with
localized ccRCC and 24 patients with primary meta-
static ccRCC were included in the study. We also in-
cluded 48 adjacent non-tumorous kidney tissues from
the localized group. All RCC cases were clinically and
pathologically confirmed to be clear cell type and were
staged according to the 2011 Union for International
Cancer Control (UICC) TNM classification of malig-
nant tumors. The nuclear grade was determined by the
Fuhrman nuclear grading system. Macrovascular inva-
sion displayed renal vein or inferior vena cava invasion
which signified tumor malignancy. Specimens were im-
mediately snap-frozen in liquid nitrogen after surgical
removal. They were stored at −80°C until analysis. Clini-
copathologic features for each of the subgroups are
given in Additional file 1: Table S1.
Cell lines, cell culture, and treatment with cobalt chloride
The ccRCC cell lines Caki-1, A498, Caki-2 as well as the hu-
man renal proximal tubular epithelial cell line HKC were
preserved in our laboratory. According to the American
Type Culture Collection, the Caki-1 cell line was metastatic
cell, whereas the A498, Caki-2 cell lines were non-
metastatic cells. The SN12-PM6 cell line was kindly pro-
vided by Dr. X.P. Zhang of the Department of Urology,
Union Hospital (Wuhan, China). The cells were cultured in
Dulbecco’s modified Eagle’s medium (HyClone), MEM-
EBSS (HyClone), McCoy's 5A Medium (HyClone), DMEM/
F12 (HyClone) with 10% fetal bovine serum (Gibco, USA),
penicillin (100 U/ml), and streptomycin (100 U/ml). All cells
were cultivated in a sterile incubator maintained at 37°C
with 5% CO2. To induce chemical hypoxia, 250 or 500 μM
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the cells were treated for 24 hours.
RNA isolation, reverse transcription and real-time PCR
The total RNA of cell lines and tissues were extracted using
Trizol reagent (Invitrogen, Carlsbad, CA) and were reverse
transcribed to cDNA via one-step RT-PCR kit (TransGen
Biotech Co., Ltd, Beijing, China) according to the manufac-
turer’s instructions. Real-time quantitative polymerase chain
reaction was performed in an Applied Biosystems 7500 De-
tection system with SYBR Green (TransGen Biotech Co.,
Ltd, Beijing, China). The relative mRNA levels of genes were
normalized to peptidylprolyl isomerase A (PPIA) [32] using
the 2-ΔΔCT method. The primer sequences are given in
Additional file 1: Table S2.
Western blot analysis
Tissues and cells were lysed using RIPA lysis buffer (Beyo-
time) and the protein concentrations were quantified
using BCA reagent (Applygen Technologies). Equivalent
amounts of protein (50–80 μg) were separated by 10%
SDS-polyacrylamide gels, and electro-transferred onto
PVDF membranes. After blocking with 5% non-fat milk
for one hour, the membranes were incubated with primary
antibodies at 4°C overnight, followed by a 10 min wash
with TBST, which was repeated three times. After this, the
membranes were incubated with the corresponding sec-
ondary antibody for one hour at room temperature. In all
specimens, rabbit anti-goat IgG-HRP, goat anti-mouse
IgG-HRP and goat anti-rabbit IgG-HRP (ZSGB-BIO) were
used as the secondary antibody at a dilution of 1:5000 re-
spectively. Immunoreactive bands were visualized using
an enhanced chemiluminescence (ECL) system (Thermo).
The mean densities of the bands were represented as the
OD in units per square millimeter and normalized to that
of β-actin (Quantity One, version 4.6.2; Bio-Rad Labora-
tories, Inc., Hercules, CA, USA). We used specific primary
antibodies detailed in Additional file 1: Table S3.
Immunohistochemistry staining (IHC)
All of the samples were fixed in 10% neutral formalin. Se-
quential sections (4 μm thick) of ccRCC specimens and their
corresponding adjacent normal renal tissue specimens were
cut from wax blocks. A standard immunostaining procedure
was then performed using a primary polyclonal goat anti-
body against human STC1 (1:100 dilution, Santa Cruz sc-
14346). Afterwards, the slides were briefly counterstained
with hematoxylin and aqueously mounted. Negative control
was performed by replacing the primary antibody with goat
serum. Immunostaining for STC1 protein was independ-
ently and blindly analyzed by two pathologists. According to
standards from a previous study [10], tissues in which more
than 10% of the cytoplasm was stained for STC1 proteinwere considered positive, and those with less than 10%
staining were considered negative.
RNAi knockdown
The small interference RNA molecules targeting human
STC1 were designed and synthesized by GenePharma Co.
(Shanghai, China). The knockdown efficiency of each siRNA
was further confirmed by in vitro transfect to cells in our
prior experiments. To enhance the silencing efficiency and
reduce potential off-target effects, the three siRNAs
(100 nM total, 33.3 nM each) were used simultaneously
to knock down STC1 in cancer cell lines using lipofecta-
mine 2000 (Invitrogen) according to the manufacturer’s
recommendations. After transfection of siRNA or nega-
tive control for 48 h, the cells were harvested for further
experiments. Sequences of siRNAs and negative control
are provided in Additional file 1: Table S4.
Construction of lentivirus (LV) for STC1 overexpression
For Plasmid construction, the coding domain sequence of
STC1 was amplified from the pcDNA3.1-STC1 by high-
fidelity PCR amplification. Primer sequences used were
sense 5’-TGCTCTAGAATGCTCCAAAACTCAG-3’ and
antisense 5’-CCGGAATTCTTATGCACTCTCATG-3’. The
resulting fragment was inserted into the lentiviral vector
PLV-EGFP (2A) Puro (Inovogen Tech. Co.) between XbaI
and EcoRI to generate PLV-EGFP-STC1. The desired se-
quence was confirmed by direct DNA sequencing. PLV-
EGFP empty vector or PLV-EGFP-STC1 was co-transfected
with pH1 and pH2 into 293 T cells, respectively, by using li-
pofectamine 2000. After transfection for 48 hours, the viral
supernatant was collected and filtered through a 0.45 μm
filter and renamed as LV-EGFP and LV-STC1, respectively.
The supernatants were used to infect Caki-2 cells with
6 μg/ml of polybrene (Sigma-Aldrich). After infection for
24 h, cells were cultured in selective medium (2 μg/ml
puromycin) to select stable cell lines. STC1 expression
was evaluated by RT-PCR and Western blotting. The
Caki-2 cells infected with LV-EGFP and LV-STC1 were
used for further analysis. Results of transfection efficiency
are shown in Additional file 1: Figure S1.
MTS assay
MTS is a tetrazolium compound, which can be bio-
reduced by cells into a colored formazan product that is
soluble in tissue culture medium. MTS assay was used to
monitor cell proliferation by absorbance. Assays were per-
formed as previously described [33]. The cells were seeded
into 96-well plates (1000 cells/well) and cultured with
200 μl of 10% FBS/medium at 37°C in a 5% CO2 incubator.
At the indicated time-points (24, 48, 72, 96 and 120 hours),
20 μl of CellTiter 96 Aqueous One Solution (Promega,
Madison, WI) was added to each well and then incubated
for 1 hour at 37°C. Absorbance was measured at 490 nm
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reader (BioTek Instruments).
Anchorage-dependent and independent growth assays
For the anchorage-dependent growth assay, Caki-1 and
A498 cells were separately seeded in six-well culture plates
after transfection for 48 hours at a density of 1 × 103 cells
per well. Colony numbers were counted after they were
fixed with methanol and stained with 0.2% crystal violet at
14 d. Caki-2 cells infected with LV-EGFP or LV-STC1
were also performed.
For the anchorage-independent growth assay, the cells
that were suspended in 0.35% top agar were plated onto
0.7% base agar in six-well plates at a density of 1 × 103 cells.
After incubating for three to four weeks, colonies were
scored.
Cell cycle analysis
After transfection for 48 hours, the Caki-1 and A498 cells
were collected, washed with phosphate-buffered saline, and
then fixed in 70% ice-cold ethanol overnight. Then the cells
were stained with propidium iodide (Beyotime, Shanghai,
China) according to the manufacturer’s instructions. DNA
analysis was performed using a FACS-Calibur (BD Biosci-
ences). Each experiment was performed in triplicate and re-
peated three times. Caki-2 cells infected with LV-EGFP or
LV-STC1 were prepared for cell cycle analysis using the
same method.
Cell migration and invasion assay
Cell migration and invasion assays were performed in 24-
well plates using Boyden chambers containing Transwell
(Corning, NY) membrane filter inserts with a pore size of
8 μm. For invasion assay, the membrane undersurface was
coated with 30 μl ECM gel from Engelbreth-Holm-Swarm
mouse sarcoma (BD Biosciences) mixed with serum-free
medium in 1:5 dilution for 4 h at 37°C. After transfection
for 48 h or infection with LV-EGFP or LV-STC1, 1 × 105
cells in serum-free medium were added to the upper
chambers, and the bottom chambers were filled with
500 μl medium containing 10% FBS. After 12 (migration)
or 24 (invasion) hours at 37°C, non-migrating cells on the
upper surface of the filters were gently scraped. Invading
and migrating cells were fixed and stained with 0.1% crys-
tal violet. The cells were randomly counted under a micro-
scope in the five representative areas on each plate. All
assays were performed independently three times.
Wound healing assay
After transfection for 48 h or infection with LV-EGFP or
LV-STC1, cell lines Caki-1, A498 and Caki-2 in interfered
group and negative control group were seeded on 6-well
plates with fresh medium containing 10% FBS. Confluent
monolayer cells were scratched using a sterile 200 μLpipette. Photos of the wound were taken at different time
points (0, 12, and 24 h after scratching). The coverage of
the scraping area was measured at three positions for each
replicate. Experiments were performed in triplicate.
Cell immunofluorescence and imaging
Immunofluorescence staining was performed as previously
described [34]. The cells were seeded and grown on glass
coverslips 24 h prior to experiment. After fixation with 4%
paraformaldehyde-PBS for 15 min, cells were then perme-
abilized in 0.5% Triton X-100 in PBS and sequentially
blocked with 3% bovine serum albumin for 30 min. The
coverslips were incubated at 37°C for 1 h with primary
antibodies recognizing STC1 (Santa Cruz), E-Cadherin
(Cell Signaling), N-Cadherin (Abcam), Vimentin (Cell Sig-
naling), α-smooth muscle actin (α-SMA) (Abcam) separ-
ately, then incubated with fluorescein isothiocyanate
(FITC)-conjugated goat anti-rabbit or goat anti-mouse
IgG at 1:200 dilution. Nuclei were stained with 0.2 mg/mL
DAPI for 15 min at 37°C. Immunofluorescence was visual-
ized under an Olympus fluorescence microscope and
image-captured. Figures were assembled using OLYMPUS
Fluoview FV1000 (version 1.6). The fluorescent micro-
scope images were assessed using Image-Pro Plus 6.0 soft-
ware, and the integral optical density (IOD) of each
photograph was collected. The primary antibodies used in
this study are given in Additional file 1: Table S3.
Statistical analysis
All data were analyzed using the SPSS statistical software
13.0(SPSS Inc., Chicago, IL), and P < 0.05 was considered
statistically significant. All continuous data were tested
for normality with the Kolmogorov-Smirnov test. Stu-
dent t test or one-way ANOVA was used to compare
normally distributed variables. The Mann–Whitney U or
Kruskal-Wallis test was used to compare continuous
variables not conforming to the assumptions of normal-
ity. The correlation of two variables was analyzed by lin-
ear regression analysis.
Results
STC1 mRNA and protein expression in ccRCC tissues and
RCC cell lines
The expression of STC1 in ccRCC tissues and RCC cell lines
was evaluated by RT-PCR and western blotting. Twenty four
primary metastatic and 48 primary non-metastatic ccRCC
tissue samples from patients were matched 1:2 according to
patient age and gender. Results indicated that the mRNA
level of STC1 was significantly up-regulated in ccRCC tis-
sues (both in localized, P < 0.01, and metastatic tissues,
P < 0.01; Figure 1A) compared with adjacent normal renal
tissues, with the greatest expression observed in metastatic
tissues (P < 0.01, Figure 1A). Elevated expression of STC1
protein was also observed in tumor tissues when compared
Figure 1 Expression of stanniocalcin-1 (STC1) in clinical samples and renal cell carcinoma (RCC) cell lines. (A) The mRNA level of STC1
was significantly up-regulated in clear cell renal cell carcinoma (ccRCC) tissues compared with adjacent normal renal tissues, with the greatest
expression observed in metastatic tissues. (B) The mRNA expression of STC1 was up-regulated in RCC cell lines compared with HKC-renal tubular
epithelial cell line, with the greatest expression observed in metastatic cells. (C) (D) Western blotting showed the changes of protein expression
were consistent with these of mRNA in clinical samples and RCC cell lines. (E) Immunofluorescence analysis revealed a significant increase in the
intensity of STC1 staining in the cytoplasm of metastatic cell lines. (F) Representative images of STC1 immunohistochemistry staining in
non-tumor (NT) tissues, localized and metastatic ccRCC tissues. Scale bar, 100 μm. Quantitative analysis of STC1 protein levels in the cytoplasm in
10 sets of paired NT tissues, localized and metastatic ccRCC tissues (n = 10). *,P < 0.05; **,P < 0.01.
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observed in metastatic tumors (Figure 1C and D). Immuno-
histochemical staining demonstrated that the STC1 protein
was predominantly localized in the cytoplasm of both renal
cancer tissues and normal renal tissues. Cytoplasmic levels
of this protein were significantly elevated in 10 metastaticccRCC tissue samples, when compared with 10 localized
ccRCC tissues and 10 normal renal tissues, a finding that
was in agreement with our results from RT-PCR and west-
ern blotting analysis (Figure 1F).
To evaluate STC1 expression in ccRCC cell in vitro,
metastatic RCC cell lines (Caki-1, SN12-PM6), non-
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imal tubular epithelial cell line HKC were analyzed by RT-
PCR and western blotting. Levels of STC1 mRNA and
protein were significantly up-regulated in ccRCC cells
when compared with normal epithelial cells (Figure 1B
and D). Furthermore, expression of STC1 mRNA and pro-
tein was found to be higher in metastatic RCC cells when
compared with non-metastatic cells. Immunofluorescence
analysis also revealed a significant increase in the intensity
of STC staining in the cytoplasm of metastatic cell lines
(Figure 1E, Additional file 1: Figure S1E).
As shown in Table 1, STC1 mRNA levels were signifi-
cantly associated with Fuhrman tumor grade (P = 0.008)
and overall TNM staging (P = 0.018).
Elevated expression of STC1 is associated with metastasis
of ccRCC at T1 stage
Given that small renal mass sometimes accompanies metas-
tasis [35], we examined whether STC1 is associated with the
metastasis of early stage ccRCC. A comparison of STC1
mRNA expression between localized and metastatic tumors,
revealed that only T1 stage tumors exhibited a statisticallyTable 1 STC1 mRNA expression in relation to ccRCC clinicopa

























*Statistically significant (P < 0.05).significant difference in STC1 expression when compared
with other tumor stages (P= 0.021, Figure 2A).
Given that tumor size has been reported to be signifi-
cantly associated with risk of metastasis [36], we next ana-
lyzed the average tumor diameter of localized and
metastatic T1 stage tumors. As shown in Figure 2B, the
average diameter of metastatic tumors (5.433 ± 0.644 cm,
n = 10) was larger than that of localized tumors (3.833 ±
1.187 cm, n = 96, P < 0.001). Furthermore, analysis of the
relationship between STC1 expression and T1 stage
ccRCC tumor size (Figure 2C) revealed that STC1 mRNA
levels correlated with average tumor diameter (n = 106,
r = 0.215, P = 0.027).
STC1 promotes cellular proliferation
Because tumor size is primarily determined by the prolifera-
tion of cancer cells, we sought to verify whether the larger
tumor size which was observed in metastatic ccRCC was a
result of elevated STC1 expression. The knockdown of
STC1 by transfection of specific siRNA was performed in
both Caki-1 and A498 cells. RT-PCR and western blotting
analysis confirmed that STC1 mRNA and protein levels inthologic features

























Figure 2 Elevated expression of STC1 is associated with metastasis of T1 stage ccRCC. Effects of STC1 interferences on cell proliferation.
(A) Analysis showing higher STC1 expression in T1 stage metastatic tumors when compared with localized tumors. (B) Analysis showing significantly
larger average diameter in metastatic tumors (5.433 ± 0.644 cm, n = 10) when compared with localized tumors (3.833 ± 1.187 cm, n = 96). (C) Positive
correlation of STC1 mRNA levels and average tumor diameter in T1 stage (n = 106, r = 0.215, p = 0.027). (D) (E) Alteration for STC1 mRNA and protein
levels in Caki-1-Metastatic cell line, A498-Non-metastatic cell line and Caki-2-Non-metastatic cell line cells after knockdown or overexpression. (F) MTS
assay showed STC1 knockdown reduced the proliferation of Caki-1 and A498 cells, while STC1 overexpression promoted the proliferation of Caki-2 cells.
(G) (H) Effects of STC1 interferences on anchorage-dependent and independent growth of RCC cells. *,P < 0.05; **,P < 0.01; ***,P < 0.001.
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(Figure 2D and E). Confirmation of STC1 overexpression in
Caki-2 cells following lentiviral infection with LV-STC1 was
also verified by RT-PCR and western blotting (Figure 2D
and E). MTS and anchorage-dependent growth assays
showed that knockdown of STC1 significantly reduced theproliferation of Caki-1 and A498 cells (P < 0.05, Figure 2F
and G), while STC1 overexpression promoted the prolifera-
tion of Caki-2 cells (P < 0.05, Figure 2F and G). Moreover, si-
lencing of STC1 in Caki-1 and A498 cells inhibited
anchorage-independent growth, while STC1 overexpression
in Caki-2 cells promoted this behavior (P < 0.05, Figure 2H).
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To evaluate whether STC1 modulates proliferation through
an effect on the cell cycle, we conducted cytometry assays.
Knockdown of STC1 in Caki-1 and A498 cells resulted in a
higher percentage of cells in G1 phase and a concomitantly
lower percentage of cells in S phase, when compared with
controls (Figure 3A and B). In contrast, STC1 overexpres-
sion in Caki-2 cells resulted in the rapid passage of cells
through the G1/S checkpoint (P < 0.05, Figure 3C). There-
fore, STC1 promotes cell cycle progression and this may in
part explain the proliferative effect of STC1 on ccRCC cells.
To investigate the mechanism underlying this change in cell
cycle progression, we examined expression of several key
cell cycle regulatory factors by western blotting. As shown
in Figure 3D, STC1 knockdown in Caki-1 cells significantly
reduced the expression of cyclin D1, cyclin-dependent kin-
ase 4 (Cdk4) and cyclin-dependent kinase 6 (Cdk6), and en-
hanced the expression of cyclin-dependent kinase inhibitor
p21. Conversely, overexpression of STC1 in Caki-2 cells ele-
vated the expression of cyclin D1, Cdk4 and Cdk6, and sup-
pressed expression of p21.Figure 3 Effect of STC1 interferences on cell cycle. (A) (B) Knockdown
in Caki-1 and A498 cells. (C) Overexpression of STC1 induced G1-S phase tr
blotting results for the expression alteration of several key cell cycle regulaSTC1 regulates the migration and invasion of ccRCC cells
in vitro
Next, we sought to determine the role of STC1 in the in-
vasion and migration of ccRCC cells. Transwell assays
were performed to evaluate the ability of A498 and Caki-1
cells to permeate the membrane (invasion assay with
Matrigel) following knockdown of STC1. Experiments re-
vealed that the migration and invasion of cancer cells were
significantly decreased following knockdown of STC1
when compared with controls (P < 0.05, Figure 4A and B).
However, STC1 overexpression had no effect on the mi-
gration and invasive of Caki-2 when compared with empty
vector group (Additional file 1: Figure S1A).
Wound healing assay revealed that knockdown of STC1
significantly reduced the cell migration at different time
points in Caki-1 (P < 0.01, Figure 4C) and A498 cells (P <
0.01, Figure 4D). As with transwell assays, however, overex-
pression of STC1 had no effect on the migratory ability of
Caki-2 cells (Additional file 1: Figure S1B).
Since epithelial–mesenchymal transition (EMT) influ-
ences ccRCC progression, we examined the expressionof STC1 led to G1 restoration compared with negative control group
ansition compared to empty vector group in Caki-2 cells. (D) Western
tory factors. *,P < 0.05; **,P < 0.01.
Figure 4 Ability of STC1 in influencing the migration and invasion of ccRCC cells in vitro. (A) (B) Representative photographs of Transwell
assays (magnification, ×100) in Caki-1 and A498 cells. (C) (D) Confluent monolayer cells were scratched using a sterile 200 μL pipette. Photos of
the wound were taken at different time points (0, 12, and 24 h after scratching). STC1 knockdown impaired the cell mobility in Caki-1 and A498
cells. Each experiment was performed triplicates. *,P < 0.05; **,P < 0.01.
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cells. Expression of the mesenchymal markers N-
cadherin, Vimentin, α-SMA, ZEB1, the epithelial marker
E-cadherin, and the matrix metalloproteinases MMP2
and MMP9 were determined by western blotting, RT-
PCR and immunofluorescence. Expression analysis
revealed that N-cadherin, Vimentin and α-SMA levels
were reduced and that E-cadherin was up-regulated in
Caki-1 and A498 cells after knockdown of STC1 (P <
0.01, Figure 5, Additional file 1: Figure S1E). Also,
MMP9 was found to be markedly down-regulated in
both Caki-1 and A498 cells (P < 0.05, Additional file 1:
Figure S1D). Considering the important roles of thesemarkers, the effect of STC1 on these EMT markers has
suggested its possible role in tumor progression.
Hypoxia induces STC1 expression
The level of STC1 mRNA correlated closely with that of
HIF-1α in ccRCC cell lines, with the exception of A498
(Figure 6A). Furthermore, a positive correlation was ob-
served between the expression of STC1 and HIF-1α
mRNA in clinical samples (n = 70, r = 0.307, P = 0.010,
Figure 6B). This result suggested that HIF-1α may regulate
STC1 expression.
To confirm this hypothesis, four RCC cell lines (Caki-1,
SN12-PM6, A498 and Caki-2) and human kidney tubule
Figure 5 Knockdown of STC1 impairs epithelial-mesenchymal transition (EMT) of Caki-1 and A498 cells. (A) (B) Forty-eight hours after
transfection, a series of EMT-related markers, including the mesenchymal markers N-cadherin, Vimentin, α-SMA, ZEB1, and the epithelial marker
E-cadherin were determined by Western blotting and immunofluorescence staining (magnification, ×600) Red, CF555; blue, DAPI. (C) Western
blotting results for the protein expression alteration of several EMT-related markers. **,P < 0.01; ***,P < 0.001.
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(CoCl2), which mimics the hypoxic state. After CoCl2
treatment, morphological changes were observed in all
cells analyzed, with the greatest changes observed for
HKC cells that were more sensitive to hypoxia than RCC
cells. Cell shrinkage and necrosis were observed and cell
density decreased. The morphological damage aggravated
with the increase of the dose of CoCl2 (Figure 6C). Under
hypoxic conditions, expression of both STC1 and HIF-1αmRNA were up-regulated in A498 cells, while only STC1
was up-regulated in Caki-2 cells (Figure 6D).
Discussion
Partial nephrectomy is recommended as a standard treat-
ment for localized ccRCC in early stage [4], and resection
of primary renal cell carcinoma can be curative. However,
distant metastasis in patients with ccRCC remains the
main cause of treatment failure and death from cancer
Figure 6 Hypoxia induces STC1 expression. (A) The mRNA expression trend of STC1 and hypoxia inducible factor-1-alpha (HIF-1α) in ccRCC
cell lines and HKC cells. (B) The association between STC1 and HIF-1α mRNA expression in clinical samples. (C) Representative images showed
the morphological changes of RCC cell lines and HKC cells after CoCl2 treatment (magnification, ×100). (D) The mRNA level changes of STC1 and
HIF-1α in A498 and Caki-2 cells after CoCl2 treatment. *,P < 0.05; **,P < 0.01; ***,P < 0.001.
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most likely to develop metastasis who may benefit from
radical nephrectomy and adjuvant treatment. Currently,
post-operative histopathological parameters are commonly
used to stratify patients [38]. But these variables are not
considered entirely reliable, and further improvement in
preoperative prediction is warranted. Thus, a molecular
biomarker, which can accurately forecast the risk of me-
tastasis in patients with early stage RCC, is required to
help guide clinical decisions.Mammalian STC1 is a ubiquitously expressed and se-
creted phosphoglycoprotein functioning in an auto-
crine/paracrine manner [20]. Studies have demonstrated
that STC1 is involved in calcium and phosphate homeo-
stasis and that it may have cytoprotective and anti-
inflammatory functions by inhibiting reactive oxygen
species [5,20,39-42]. Recently, a series of studies re-
vealed the involvement of STC1 in cancer progression
and metastasis [10,22,26,27,43,44], which motivated us
to focus on the role of STC1 in ccRCC development and
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has never been characterized. Yang et al. [45] observed
that HIF-1α may participate in the malignant prolifera-
tion of renal carcinoma cells by promoting STC1 accu-
mulation or by down-regulating Ca2+, but such an effect
may gradually attenuate because of the inhibitory effect
of STC1 on HIF-1α.
In this work, we found that both STC1 mRNA and pro-
tein levels were up-regulated in ccRCC tissues when com-
pared to their matched adjacent non-tumor counterparts.
More importantly, STC1 expression levels were elevated to
a greater extent in ccRCC tissues associated with distant
metastasis. For further confirmation, we examined STC1 ex-
pression in ccRCC cell lines. In agreement with our tissue
findings, STC1 was found to be highly expressed in ccRCC
cell lines, with the greatest levels of STC1 expression being
observed in metastatic cell lines. These data are consistent
with observations reported for the majority of malignancies
[10,22,23,46,47], although with the exception of cervical can-
cer [48].
Our analysis of STC1 mRNA expression in ccRCC tumors
of different stages revealed that STC1 expression was up-
regulated in T1 stage metastatic tumors when compared
with localized tumors. Also, STC1 mRNA expression in T2
and T3 metastatic tumors was much higher than that in lo-
calized tumors, which barely achieved statistical significance.
Previous studies have reported that tumor size is a risk fac-
tor in the metastasis of T1 stage RCC, with the synchronous
metastasis rate increasing with tumor size [49,50]. In our
study, we identified a positive correlation between STC1 ex-
pression and average tumor diameter.
Because tumor size primarily determined by the prolifera-
tive ability of tumor cells, we examined whether the larger
tumor size observed in metastatic ccRCC was a result of
high levels of STC1 expression. In agree with previous stud-
ies [10,14,44], knockdown of STC1 decreased proliferation
and led to G1 arrest in ccRCC cell lines (Caki-1 and A498).
Conversely, overexpression of STC1 in Caki-2 enhanced
proliferation and induced G1/S transition. Furthermore, we
found that knockdown or overexpression of STC1 caused a
marked alteration in the expression of cyclin D1, Cdk4,
Cdk6 and p21, all of which are key proteins in the regulation
of cell cycle control. Liu et al. [10] reported that STC1 over-
expression increased the expression of cyclin A, cyclin B1,
CDK2, and a short cyclin E isoform in ovarian cancer cells,
and it is possible that the elevated expression of these
proteins is required for the regulation of G1 to S phase
transition. However, Murai et al. [27] reported that overex-
pression of STC1 had no effect on the proliferation of
MDA-MB-231 human breast cancer cells. Inconsistencies
regarding the effect of STC1 on cancer cell proliferation
may be owing to the different mechanisms exploited by
tumor cells to promote growth and survival. Taken together,
our data indicate that STC1 drives tumor cell growth andproliferation, and is consistent with the tumor growth, and
ultimately the metastasis observed for early stage ccRCC.
Invasion and migration are two key features of metastatic
malignancies, and are thought to increase the metastatic po-
tential of cancer cells. In the current study, we found that
STC1 silencing suppressed the migration and invasion of
renal cancer cells, whereas overexpression of STC1 had no
effect on these aspects of cell behavior. A possible reason for
the lack of a migratory phenotype associated with STC1
overexpression is that basal STC1 expression in Caki-2 cells
already exceeds the threshold required for these functions.
EMT has been defined as a possible mechanism of metasta-
sis; it can transform epithelial tumor cells and confer the
mesenchymal characteristics that would facilitate the dis-
semination of these cells, leading to metastases. Because it
has previously been reported that EMT influences ccRCC
progression [51], we examined the expression of a series of
EMT-related markers. Expression of the mesenchymal
markers N-cadherin, Vimentin, α-SMA and MMP9, and the
epithelial marker E-cadherin were altered as a result of
STC1 silencing in Caki-1 and A498 cells. Law et al. [14]
showed that overexpression of STC1 in HUVEC cells stimu-
lated migration, and induced Vimentin expression. The ef-
fects of STC1 induced HUVEC remodeling were further
exemplified by a concomitant increased in the expression
and activity of MMP2 and a decrease in its endogenous in-
hibitor, tissue inhibitor of matrix metalloproteinase
(TIMP1). Murai et al. [27] have reported that secreted STC1
promotes the metastatic potential of breast cancer cells via
activation the of PI3K/AKT signaling axis. Other research
has identified STC1 as a mediator of metastasis associated
with PDGF receptor function in the colorectal cancer setting
[44]. PDGF-stimulated fibroblasts were shown to increase
the migration and invasion of co-cultured colorectal cancer
cells in an STC1-dependent manner. In an orthotopic
mouse model of colorectal cancer, cells from tumors formed
in the presence of STC1-deficient fibroblasts displayed re-
duced intravasation, resulting in fewer and smaller distant
metastases [44]. These data indicate that the increase in
metastatic potential and malignancy promoted by STC1 in
ccRCC cells is linked to EMT-related markers such as E-
cadherin, N-cadherin, Vimentin, α-SMA and MMP9 which
function to degrade the vascular wall. The result was con-
sistent with the finding that higher STC1 expression in
ccRCC was associated with higher Fuhrman grade and over-
all TNM staging. In mammals, an important role of STC1
has also been suggested during gestation, in the placenta
[52], ovaries [12] and and endometrium [53,54]. Like cancer
cells, placental cells are characterized by invasive nature and
migratory properties which may partly support the function
of STC1 in ccRCC cells.
A number of studies have reported that STC1 is associ-
ated with hypoxia and the major hypoxia-regulated factor
HIF-1α [20,30,31]. Law et al. [31] have shown that
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gene promoter and transactivates STC1 expression. In this
study, hypoxic conditions were found to up-regulate
mRNA for both STC1 and HIF-1α in von Hippel-Lindau
(VHL) -deficient A498 cells, whereas only STC1 mRNA
was up-regulated in Caki-2 cells. The reason for this may
be the differential expression of VHL protein in these
cells, given that wild-type VHL protein acts to prevent
HIF-1α accumulation. Perhaps, these are some other fac-
tors regulating STC1 expression in hypoxia condition may
account for the inconsistency of STC1 and HIF-1α in
Caki-2 cells. HIF-1 plays a central role in RCC carcinogen-
esis and progression [55,56]. In the current study, we show
for the first time the relationship between STC1 and hyp-
oxia both in clinical samples of ccRCC and in vitro in
ccRCC cell lines. Our data provide an insight into the pos-
sible role of STC1 in renal cancer cell survival under hyp-
oxic conditions.
Conclusions
To the best of our knowledge, this is the first time that
STC1 has been implicated as a biomarker associated with
the progression and metastasis of ccRCC. Here, we demon-
strate that STC1 is associated with the metastasis of early
stage ccRCC by regulating the proliferation, cell cycle, mi-
gration and invasion of tumor cells. This new biomarker
may be helpful both for guiding clinical decisions when con-
sidering surgical options and adjuvant treatment, and for
the prediction of ccRCC outcome. Hypoxia and HIF-1α
were identified as candidate regulators of STC1 expression.
Future experiments and research should focus on the bio-
logical roles of STC1 in vivo and the underlying mechanism
of its action.
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